Literature DB >> 22670880

Prognostic categories for amyotrophic lateral sclerosis.

William J Scotton1, Kirsten M Scott, Dan H Moore, Leeza Almedom, Lokesh C Wijesekera, Anna Janssen, Catherine Nigro, Mohammed Sakel, Peter N Leigh, Chris Shaw, Ammar Al-Chalabi.   

Abstract

Our objective was to generate a prognostic classification method for amyotrophic lateral sclerosis (ALS) from a prognostic model built using clinical variables from a population register. We carried out a retrospective multivariate analysis of 713 patients with ALS over a 20-year period from the South-East England Amyotrophic Lateral Sclerosis (SEALS) population register. Patients were randomly allocated to 'discovery' or 'test' cohorts. A prognostic score was calculated using the discovery cohort and then used to predict survival in the test cohort. The score was used as a predictor variable to split the test cohort in four prognostic categories (good, moderate, average, poor). The accuracy of the score in predicting survival was tested by checking whether the predicted survival fell within the actual survival tertile which that patient was in. A prognostic score generated from one cohort of patients predicted survival for a second cohort of patients (r(2) = 0.72). Six variables were included in the survival model: age at onset, diagnostic delay, El Escorial category, use of riluzole, gender and site of onset. Cox regression demonstrated a strong relationship between these variables and survival (χ(2) 80.8, df 1, p < 0.0001, n = 343) in the test cohort. Kaplan-Meier analysis demonstrated a significant difference in survival between clinical categories (log rank 161.932, df 3, p < 0.001), and the prognostic score generated for the test cohort accurately predicted survival in 64% of the patients. In conclusion, it is possible to correctly classify patients into prognostic categories using clinical data easily available at time of diagnosis.

Entities:  

Mesh:

Year:  2012        PMID: 22670880     DOI: 10.3109/17482968.2012.679281

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler        ISSN: 1471-180X


  7 in total

Review 1.  Clinical neurogenetics: amyotrophic lateral sclerosis.

Authors:  Matthew B Harms; Robert H Baloh
Journal:  Neurol Clin       Date:  2013-11       Impact factor: 3.806

Review 2.  Prognostic factors for the course of functional status of patients with ALS: a systematic review.

Authors:  Huub Creemers; Hepke Grupstra; Frans Nollet; Leonard H van den Berg; Anita Beelen
Journal:  J Neurol       Date:  2014-11-11       Impact factor: 4.849

3.  Predicting prognosis in amyotrophic lateral sclerosis: a simple algorithm.

Authors:  Marwa Elamin; Peter Bede; Anna Montuschi; Niall Pender; Adriano Chio; Orla Hardiman
Journal:  J Neurol       Date:  2015-04-11       Impact factor: 4.849

4.  Deep learning predictions of survival based on MRI in amyotrophic lateral sclerosis.

Authors:  Hannelore K van der Burgh; Ruben Schmidt; Henk-Jan Westeneng; Marcel A de Reus; Leonard H van den Berg; Martijn P van den Heuvel
Journal:  Neuroimage Clin       Date:  2016-10-11       Impact factor: 4.881

Review 5.  Quantifying disease progression in amyotrophic lateral sclerosis.

Authors:  Neil G Simon; Martin R Turner; Steve Vucic; Ammar Al-Chalabi; Jeremy Shefner; Catherine Lomen-Hoerth; Matthew C Kiernan
Journal:  Ann Neurol       Date:  2014-09-30       Impact factor: 10.422

6.  Use of the interRAI CHESS scale to predict mortality among persons with neurological conditions in three care settings.

Authors:  John P Hirdes; Jeffrey W Poss; Lori Mitchell; Lawrence Korngut; George Heckman
Journal:  PLoS One       Date:  2014-06-10       Impact factor: 3.240

7.  Identification and outcomes of clinical phenotypes in amyotrophic lateral sclerosis/motor neuron disease: Australian National Motor Neuron Disease observational cohort.

Authors:  Paul Talman; Thi Duong; Steve Vucic; Susan Mathers; Svetha Venkatesh; Robert Henderson; Dominic Rowe; David Schultz; Robert Edis; Merrilee Needham; Richard Macdonnell; Pamela McCombe; Carol Birks; Matthew Kiernan
Journal:  BMJ Open       Date:  2016-09-30       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.